Format

Send to

Choose Destination
Ann Transl Med. 2019 Feb;7(4):77. doi: 10.21037/atm.2019.01.39.

Mortality after hip resurfacing versus total hip arthroplasty in young patients: a single surgeon experience.

Author information

1
Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, OH, USA.
2
Department of Orthopaedic Surgery, Lenox Hill Hospital, New York, NY, USA.

Abstract

Background:

The aims of this study were to investigate the following questions: (I) what are the mortality rates in patients age 55 years and younger who underwent a hip resurfacing arthroplasty (HRA) versus a standard total hip arthroplasty (THA)? (II) is the type of operation independently associated with mortality?

Methods:

The database of a single high-volume surgeon was reviewed for patient's age 55 years and younger who underwent a hip arthroplasty between 2002 and 2010. This yielded 505 HRA patients and 124 THA patients. Chi-square analysis was performed to identify a 5-year mortality rate difference between the two cohorts. Multivariable Cox-Regression analyses were used to determine whether the type of operation was independently associated with mortality.

Results:

There were 8 mortalities (1.6%) in the HRA cohort and 11 (8.9%) in the THA cohort, a statistically significant difference (P<0.001) on univariate analysis. Low mortality rates produced underpowered multivariate models.

Conclusions:

We have demonstrated that patients age 55 and younger who undergo HRA have a significantly lower mortality rate than those undergoing THA. This is consistent with multiple previously published large database studies.

KEYWORDS:

Birmingham Hip Resurfacing (BHR); Mortality; hip resurfacing; total hip arthroplasty (THA)

Conflict of interest statement

Conflicts of Interest: PJ Brooks is a Paid consultant of Smith & Nephew and Zimmer. D Brigati is a Board or committee member of AAOS. AS Greenwald reports the following: 4Web: Research support; AAOS: Board or committee member; Applied Medical Technologies: Research support; Arthrex, Inc.: Research support; Clinical Orthopaedics and Related Research: Editorial or governing board; Conformis: Research support; DePuy, A Johnson & Johnson Company: Research support; Journal of Arthroplasty: Editorial or governing board; Journal of Bone and Joint Surgery - American: Editorial or governing board; Lima Corporate: Research support; Materialise: Research support; Orthopaedic Research and Education Foundation: Board or committee member; Orthopedics: Editorial or governing board; Orthopedics Today: Editorial or governing board; Renovis: Research support; Seminars in Arthroplasty: Publishing royalties, financial or material support; Smith & Nephew: Paid presenter or speaker; The Bone & Joint Journal: Editorial or governing board; Total Joint Orthopedics (TJO): Research support; Waldemar Link: Research support; Zimmer Biomet: Research support. MA Mont reports the following: AAOS: Board or committee member; American Association of Hip and Knee Surgeons: Board or committee member; Cymedica: Paid consultant; DJ Orthopaedics: Paid consultant; Research support; Flexion Therapeutics: Paid consultant; Johnson & Johnson: Paid consultant; Research support; Journal of Arthroplasty: Editorial or governing board; Journal of Knee Surgery: Editorial or governing board; Knee Society: Board or committee member; Medicus Works LLC: Publishing royalties, financial or material support; Microport: IP royalties; National Institutes of Health (NIAMS & NICHD): Research support; Ongoing Care Solutions: Paid consultant; Research support; Orthopedics: Editorial or governing board; Orthosensor: Paid consultant; Research support; Pacira: Paid consultant; Peerwell: Paid consultant; Stock or stock Options; Performance Dynamics: Paid consultant; Pfizer: Paid consultant; Skye Biologics: Paid consultant; Stryker: IP royalties; Paid consultant; Research support; Surgical Techniques International: Editorial or governing board; Tissue Gene: Paid consultant; TissueGene: Research support; Up-to Date: Publishing royalties, financial or material support; USMI: Stock or stock Options; Wolters Kluwer Health - Lippincott Williams & Wilkins: Publishing royalties, financial or material support. Other authors have no conflicts of interest to declare.

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center